HIREMII LIMITED

ACN 642 994 214

NOTICE OF ANNUAL GENERAL MEETING

The annual general meeting of Hiremii Limited will be held at 12.00pm (AWST) on Thursday, 27 November 2025 at the offices of RSM, Level 32, 2 The Esplanade, Perth, Western Australia

This Notice should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their accountant, solicitor or other professional adviser prior to voting.

Shareholders may vote by directed proxy in lieu of attending the Meeting in person. Proxy forms for the Meeting should be lodged before 12.00pm (AWST) on Tuesday, 25 November 2025.

Shareholders can also submit, and are encouraged to submit, any questions in advance of the Meeting by emailing the questions to info@hiremii.com by no later than 5.00pm (AWST) on Tuesday, 25 November 2025.

If the above arrangements with respect to the Meeting change, Shareholders will be updated via the ASX Market Announcements Platform and on the Company's website at www.hiremii.com.

Should you wish to discuss any matter please do not hesitate to contact the Company at info@hiremii.com or by telephone on +61 2 7259 1501.

HIREMII LIMITED
ACN 642 994 214

NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given that the annual general meeting of shareholders of Hiremii Limited (**Company**) will be held at 12.00pm (AWST) on Thursday, 27 November 2025 at the offices of RSM, Level 32, 2 The Esplanade, Perth, Western Australia (**Meeting**).

The Explanatory Memorandum provides additional information on matters to be considered at the Meeting. The Explanatory Memorandum and the Proxy Form form part of the Notice.

The Directors have determined pursuant to regulation 7.11.37 of the *Corporations Regulations 2001* (Cth) that the persons eligible to vote at the Meeting are those who are registered as Shareholders on Tuesday, 25 November 2025 at 4.00pm (AWST).

Terms and abbreviations used in the Notice and the Explanatory Memorandum will, unless the context requires otherwise, have the meaning given to them in Schedule 1.

AGENDA

Annual Report

To consider the Annual Report of the Company and its controlled entities for the financial year ended 30 June 2025, which includes the Financial Report, the Directors' Report and the Auditor's Report.

1 Resolution 1 – Remuneration Report

To consider and, if thought fit, to pass with or without amendment, as a **non-binding resolution** the following:

"That, pursuant to and in accordance with section 250R(2) of the Corporations Act and for all other purposes, Shareholders approve the adoption of the Remuneration Report on the terms and conditions in the Explanatory Memorandum."

Note: The vote on this Resolution is advisory only and does not bind the Directors or the Company. Shareholders are encouraged to read the Explanatory Memorandum for further details on the consequences of voting on this Resolution.

Voting Prohibition

A vote on this Resolution must not be cast (in any capacity) by or on behalf of any of the following persons:

(a) a member of the Key Management Personnel details of whose remuneration are included in the Remuneration Report; or

(b) a Closely Related Party of such a member.

However, a person described above may cast a vote on this Resolution if the vote is not cast on behalf of a person described in subparagraphs (a) or (b) above and either:

(a) the person is appointed as a proxy by writing that specifies the way the proxy is to vote on this Resolution; or

(b) the person is the Chairperson and the appointment of the Chairperson as proxy does not specify the way the proxy is to vote on this Resolution but expressly authorises the Chairperson to exercise the proxy, even if this Resolution is connected directly or indirectly with the remuneration of a member of the Key Management Personnel.

2 Resolution 2 – Re-Election of Mr David Buckingham as Director

To consider and, if thought fit, to pass with or without amendment, as an **ordinary resolution** the following:

"That, pursuant to and in accordance with Listing Rule 14.5, article 7.3(c) of the Constitution and for all other purposes, Mr David Buckingham, a Director, retires and being eligible, is re-elected as a Director on the terms and conditions in the Explanatory Memorandum."

3 Resolution 3 – Approval of 10% Placement Facility

To consider and, if thought fit, to pass with or without amendment, as a **special resolution** the following:

"That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, Shareholders approve the issue of Equity Securities of up to 10% of the issued capital of the Company (at the time of the issue) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions in the Explanatory Memorandum."

Voting Exclusion

If at the time the approval is sought, the entity is proposing to make an issue of securities under Listing Rule 7.1A.2, the Company will disregard any votes cast in favour of this Resolution by or on behalf of a person who is expected to participate in the proposed issue or who will obtain a material benefit as a result of the proposed issue of securities (except a benefit solely in the capacity of a holder of ordinary securities in the entity) or an associate of that person (or those persons).

However, this does not apply to a vote cast in favour of this Resolution by:

(a) a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with directions given to the proxy or attorney to vote on this Resolution in that way; or

(b) the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

    (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on this Resolution; and

    (ii) the holder votes on this Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

Note: As at the date of the Notice, it is not known who may participate in any Equity Securities issued under Resolution 3 and has not approached any Shareholder or identified a class of existing Shareholders to participate in any issue of Equity Securities under the 10% Placement Facility. Accordingly, no Shareholders are excluded from voting on Resolution 3.

4 Resolution 4 – Ratification of T1 Placement Shares issued under Listing Rule 7.1A

To consider and, if thought fit, to pass with or without amendment, as an **ordinary resolution** the following:

"That, pursuant to and in accordance with Listing Rule 7.4 and for all other purposes, Shareholders ratify the prior issue of 13,690,475 Shares issued under Listing Rule 7.1A, pursuant to the Tranche 1 Placement on the terms and conditions in the Explanatory Memorandum."

Voting Exclusion

The Company will disregard any votes cast in favour of this Resolution by or on behalf of a person who participated in the Tranche 1 Placement or any associates of those persons.

However, this does not apply to a vote cast in favour of this Resolution by:

(a) a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with directions given to the proxy or attorney to vote on this Resolution that way; or

(b) the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

   (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on this Resolution; and

   (ii) the holder votes on this Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

5 Resolution 5 – Ratification of T1 Placement Options issued under Listing Rule 7.1

To consider and, if thought fit, to pass with or without amendment, as an **ordinary resolution** the following:

"That, pursuant to and in accordance with Listing Rule 7.4 and for all other purposes, Shareholders ratify the prior issue of 13,690,475 Options issued under Listing Rule 7.1, pursuant to the Tranche 1 Placement on the terms and conditions in the Explanatory Memorandum."

Voting Exclusion

The Company will disregard any votes cast in favour of this Resolution by or on behalf of a person who participated in the Tranche 1 Placement or any associates of those persons.

However, this does not apply to a vote cast in favour of this Resolution by:

(a) a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with directions given to the proxy or attorney to vote on this Resolution that way; or

(b) the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

(i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on this Resolution; and

(ii) the holder votes on this Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

6 Resolution 6 – Issue of Tranche 2 Placement Shares to Mr Andrew Hornby

To consider and, if thought fit, to pass with or without amendment, as an **ordinary resolution** the following:

"That, pursuant to and in accordance with Listing Rule 10.11, Chapter 2E of the Corporations Act (including section 208 of the Corporations Act) and for all other purposes, Shareholders approve the issue of up to 833,333 Shares to Mr Andrew Hornby (and/or his nominee(s)) pursuant to the Tranche 2 Placement, on the terms and conditions in the Explanatory Memorandum."

Voting Exclusion

The Company will disregard any votes cast in favour of this Resolution by or on behalf of Mr Andrew Hornby (and/or his nominee(s)) and any other person who will obtain a material benefit as a result of the proposed issue of the Shares (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of Mr Andrew Hornby or of any of the other abovementioned persons.

However, this does not apply to a vote cast in favour of this Resolution by:

(a) a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with directions given to the proxy or attorney to vote on this Resolution in that way; or

(b) the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

(i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on this Resolution; and

(ii) the holder votes on this Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

Voting Prohibition

In accordance with section 224 of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of Mr Andrew Hornby or his nominee(s) or any of his, or their, associates. However, subject to the voting exclusion above and the further voting prohibition below, this does not prevent the casting of a vote if:

(a) it is cast by a person as a proxy appointed by writing that specifies how the proxy is to vote on this Resolution; and

(b) it is not cast on behalf of Mr Andrew Hornby or his nominee(s) or any of his, or their, associates.

7 Resolution 7 – Issue of Tranche 2 Placement Options to Mr Andrew Hornby

To consider and, if thought fit, to pass with or without amendment, as an **ordinary resolution** the following:

"That, subject to and conditional upon the passing of Resolution 6, pursuant to and in accordance with Listing Rule 10.11, Chapter 2E of the Corporations Act (including section 208 of the Corporations Act) and for all other purposes, Shareholders approve the issue of up to 833,333 Options to Mr Andrew Hornby (and/or his nominee(s)) pursuant to the Tranche 2 Placement, on the terms and conditions in the Explanatory Memorandum."

Voting Exclusion

The Company will disregard any votes cast in favour of this Resolution by or on behalf of Mr Andrew Hornby (and/or his nominee(s)) and any other person who will obtain a material benefit as a result of the proposed issue of the Options (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of Mr Andrew Hornby or of any of the other abovementioned persons.

However, this does not apply to a vote cast in favour of this Resolution by:

(a) a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with directions given to the proxy or attorney to vote on this Resolution in that way; or

(b) the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

    (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on this Resolution; and

    (ii) the holder votes on this Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

Voting Prohibition

In accordance with section 224 of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of Mr Andrew Hornby or his nominee(s) or any of his, or their, associates. However, subject to the voting exclusion above and the further voting prohibition below, this does not prevent the casting of a vote if:

(a) it is cast by a person as a proxy appointed by writing that specifies how the proxy is to vote on this Resolution; and

(b) it is not cast on behalf of Mr Andrew Hornby or his nominee(s) or any of his, or their, associates.

8 Resolution 8 – Issue of Tranche 2 Placement Shares to Ms Sophie Chen

To consider and, if thought fit, to pass with or without amendment, as an **ordinary resolution** the following:

"That, pursuant to and in accordance with Listing Rule 10.11, Chapter 2E of the Corporations Act (including section 208 of the Corporations Act) and for all other purposes, Shareholders approve the issue of up to 714,286 Shares to Ms Sophie Chen (and/or her nominee(s))

pursuant to the Tranche 2 Placement, on the terms and conditions in the Explanatory Memorandum."

Voting Exclusion

The Company will disregard any votes cast in favour of this Resolution by or on behalf of Ms Sophie Chen (and/or her nominee(s)) and any other person who will obtain a material benefit as a result of the proposed issue of the Shares (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of Ms Sophie Chen or of any of the other abovementioned persons.

However, this does not apply to a vote cast in favour of this Resolution by:

(a) a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with directions given to the proxy or attorney to vote on this Resolution in that way; or

(b) the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

    (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on this Resolution; and

    (ii) the holder votes on this Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

Voting Prohibition

In accordance with section 224 of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of Ms Sophie Chen or her nominee(s) or any of her, or their, associates. However, subject to the voting exclusion above and the further voting prohibition below, this does not prevent the casting of a vote if:

(a) it is cast by a person as a proxy appointed by writing that specifies how the proxy is to vote on this Resolution; and

(b) it is not cast on behalf of Ms Sophie Chen or her nominee(s) or any of her, or their, associates.

9 Resolution 9 – Issue of Tranche 2 Placement Options to Ms Sophie Chen

To consider and, if thought fit, to pass with or without amendment, as an **ordinary resolution** the following:

"That, subject to and conditional upon the passing of Resolution 8, pursuant to and in accordance with Listing Rule 10.11, Chapter 2E of the Corporations Act (including section 208 of the Corporations Act) and for all other purposes, Shareholders approve the issue of up to 714,286 Options to Ms Sophie Chen (and/or her nominee(s)) pursuant to the Tranche 2 Placement, on the terms and conditions in the Explanatory Memorandum."

Voting Exclusion

The Company will disregard any votes cast in favour of this Resolution by or on behalf of Ms Sophie Chen (and/or her nominee(s)) and any other person who will obtain a material benefit as a result of the proposed issue of the Options (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of Ms Sophie Chen or of any of the other abovementioned persons.

However, this does not apply to a vote cast in favour of this Resolution by:

(a) a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with directions given to the proxy or attorney to vote on this Resolution in that way; or

(b) the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

  (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on this Resolution; and

  (ii) the holder votes on this Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

Voting Prohibition

In accordance with section 224 of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of Ms Sophie Chen or her nominee(s) or any of her, or their, associates. However, subject to the voting exclusion above and the further voting prohibition below, this does not prevent the casting of a vote if:

(a) it is cast by a person as a proxy appointed by writing that specifies how the proxy is to vote on this Resolution; and

(b) it is not cast on behalf of Ms Sophie Chen or her nominee(s) or any of her, or their, associates.

10 Resolution 10 – Issue of Tranche 2 Placement Shares to Mr Conor O'Brien

To consider and, if thought fit, to pass with or without amendment, as an **ordinary resolution** the following:

"That, pursuant to and in accordance with Listing Rule 10.11, Chapter 2E of the Corporations Act (including section 208 of the Corporations Act) and for all other purposes, Shareholders approve the issue of up to 238,095 Shares to Mr Conor O'Brien (and/or his nominee(s)) pursuant to the Tranche 2 Placement, on the terms and conditions in the Explanatory Memorandum."

Voting Exclusion

The Company will disregard any votes cast in favour of this Resolution by or on behalf of Mr Conor O'Brien (and/or his nominee(s)) and any other person who will obtain a material benefit as a result of the proposed issue of the Shares (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of Mr Conor O'Brien or of any of the other abovementioned persons.

However, this does not apply to a vote cast in favour of this Resolution by:

(a) a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with directions given to the proxy or attorney to vote on this Resolution in that way; or

(b) the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

  (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on this Resolution; and

(ii) the holder votes on this Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

Voting Prohibition

In accordance with section 224 of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of Mr Conor O'Brien or his nominee(s) or any of his, or their, associates. However, subject to the voting exclusion above and the further voting prohibition below, this does not prevent the casting of a vote if:

(a) it is cast by a person as a proxy appointed by writing that specifies how the proxy is to vote on this Resolution; and

(b) it is not cast on behalf of Mr Conor O'Brien or his nominee(s) or any of his, or their, associates.

11 Resolution 11 – Issue of Tranche 2 Placement Options to Mr Conor O'Brien

To consider and, if thought fit, to pass with or without amendment, as an **ordinary resolution** the following:

"That, subject to and conditional upon the passing of Resolution 10, pursuant to and in accordance with Listing Rule 10.11, Chapter 2E of the Corporations Act (including section 208 of the Corporations Act) and for all other purposes, Shareholders approve the issue of up to 238,095 Options to Mr Conor O'Brien (and/or his nominee(s)) pursuant to the Tranche 2 Placement, on the terms and conditions in the Explanatory Memorandum."

Voting Exclusion

The Company will disregard any votes cast in favour of this Resolution by or on behalf of Mr Conor O'Brien (and/or his nominee(s)) and any other person who will obtain a material benefit as a result of the proposed issue of the Options (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of Mr Conor O'Brien or of any of the other abovementioned persons.

However, this does not apply to a vote cast in favour of this Resolution by:

(a) a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with directions given to the proxy or attorney to vote on this Resolution in that way; or

(b) the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

(i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on this Resolution; and

(ii) the holder votes on this Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

Voting Prohibition

In accordance with section 224 of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of Mr Conor O'Brien or his nominee(s) or any of his, or their, associates. However, subject to the voting exclusion above and the further voting prohibition below, this does not prevent the casting of a vote if:

(a) it is cast by a person as a proxy appointed by writing that specifies how the proxy is to vote on this Resolution; and

(b) it is not cast on behalf of Mr Conor O'Brien or his nominee(s) or any of his, or their, associates.

12 Resolution 12 – Issue of Director Shares to Ms Sophie Chen in lieu of Director Fees

To consider and, if thought fit, to pass with or without amendment, as an **ordinary resolution** the following:

"That, pursuant to and in accordance with Listing Rule 10.11 and for all other purposes, Shareholders approve the issue of Shares to Ms Sophie Chen (and/or her nominee(s)) based on the formula detailed in the Explanatory Memorandum, on the terms and conditions in the Explanatory Memorandum."

Voting Exclusion

The Company will disregard any votes cast in favour of this Resolution by or on behalf of Ms Sophie Chen (and/or her nominee(s)) and any other person who will obtain a material benefit as a result of the proposed issue of Director Shares (except a benefit solely by reason of being a holder of ordinary securities in the Company or an associate of Ms Sophie Chen or any of the abovementioned persons.

However, this does not apply to a vote cast in favour of this Resolution by:

(a) a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with directions given to the proxy or attorney to vote on this Resolution in that way; or

(b) the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or

(c) a holder acting in a nominee, trustee or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

    (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on this Resolution; and

    (ii) the holder votes on this Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

Voting Prohibition

In accordance with section 250BD of the Corporations Act, a vote on this Resolution must not be cast by a person appointed as a proxy, where that person is either a member of the Key Management Personnel or a Closely Related Party of such member.

However, a vote may be cast by such person if the vote is not cast on behalf of a person who is otherwise excluded from voting, and:

(a) the person is appointed as a proxy and the appointment specifies how the proxy is to vote; or

(b) the person appointed as proxy is the Chairperson and the appointment does not specify how the Chairperson is to vote but expressly authorises the Chairperson to exercise the proxy even if the Resolution is connected with the remuneration of a member of the Key Management Personnel.

13 Resolution 13 – Section 195 Approval

To consider and, if thought fit, to pass with or without amendment, as an **ordinary resolution** the following:

"That, pursuant to and in accordance with subsection 195(4) of the Corporations Act and for all other purposes, Shareholders approve the transactions contemplated in Resolutions 6 to 11 (inclusive)."

By order of the Board



Susan Park
Company Secretary
Dated: 15 October 2025

HIREMII LIMITED
ACN 642 994 214

EXPLANATORY MEMORANDUM

1 Introduction

This Explanatory Memorandum has been prepared for the information of Shareholders in connection with the business to be conducted at the Meeting.

This Explanatory Memorandum should be read in conjunction with and forms part of the Notice. The purpose of this Explanatory Memorandum is to provide information to Shareholders in deciding whether or not to pass the Resolutions:

Section 2:	Action to be taken by Shareholders
Section 3:	Annual Report
Section 4:	Resolution 1 – Remuneration Report
Section 5:	Resolution 2 – Re-election of Mr David Buckingham as Director
Section 6:	Resolution 3 – Approval of 10% Placement Facility
Section 7:	Resolution 4 – Ratification of T1 Placement Shares issued under Listing Rule 7.1A
Section 8:	Resolution 5 – Ratification of T1 Placement Options issued under Listing Rule 7.1
Section 9:	Resolutions 6, 8 and 10 – Issue of Tranche 2 Placement Shares to Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien
Section 10:	Resolutions 7, 9 and 11 – Issue of Tranche 2 Placement Options to Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien
Section 11:	Resolution 12 – Issue of Director Shares to Ms Sophie Chen in lieu of Director Fees
Section 12:	Section 195 Approval
Schedule 1:	Definitions
Schedule 2:	Terms and Conditions of Placement Options

A Proxy Form is located at the end of this Explanatory Memorandum.

2 Action to be taken by Shareholders

Shareholders should read the Notice including this Explanatory Memorandum carefully before deciding how to vote on the Resolutions.

The Company advises that a poll will be conducted for all Resolutions.

2.1 Proxies

A Proxy Form is attached to the Notice. This is to be used by Shareholders if they wish to appoint a representative (a 'proxy') to vote in their place. All Shareholders are invited and encouraged to attend the Meeting or, if they are unable to attend in person, sign and return the Proxy Form to the Company in accordance with the instructions thereon. Lodgement of a Proxy Form will not preclude a Shareholder from attending and voting at the Meeting (subject to the voting exclusions detailed in the Notice).

Please note that:

(a) a member of the Company entitled to attend and vote at the Meeting is entitled to appoint a proxy;

(b) a proxy need not be a member of the Company; and

(c) a member of the Company entitled to cast two or more votes may appoint two proxies and may specify the proportion or number of votes each proxy is appointed to exercise. Where the proportion or number is not specified, each proxy may exercise half of the votes.

If a Shareholder appoints a body corporate as its proxy and the body corporate wishes to appoint an individual as its representative, the body corporate should provide that person with a certificate or letter executed in accordance with the Corporations Act authorising him or her to act as that body corporate's representative. The authority may be sent to the Company or its share registry in advance of the Meeting or handed in at the Meeting when registering as a corporate representative

Proxy Forms must be received by the Company no later than 12.00pm (AWST) on Tuesday, 25 November 2025, being at least 48 hours before the Meeting.

The Proxy Form provides further details on appointing proxies and lodging Proxy Forms.

2.2 Voting Prohibition by Proxy holders (Remuneration of Key Management Personnel)

(a) Resolution 1

A vote on Resolution 1 must not be cast (in any capacity) by or on behalf of any of the following persons:

(i) a member of the Key Management Personnel details of whose remuneration are included in the Remuneration Report; or

(ii) a Closely Related Party of such member.

However, a vote may be cast by such persons if the vote is not cast on behalf of a person who is excluded from voting on Resolution 1, and:

(iii) the person is appointed as a proxy that specifies the way the proxy is to vote on this Resolution; or

(iv) the person is the Chairperson and the appointment of the Chairperson as proxy does not specify the way the proxy is to vote on Resolution 1, but expressly authorises the Chairperson to exercise the proxy even if Resolution 1 is connected directly or indirectly with the remuneration of a member of the Key Management Personnel.

(b) Resolution 12

A vote on Resolution 12 must not be cast by a person appointed as a proxy, where that person is either a member of the Key Management Personnel or a Closely Related Party of such member.

However, a vote may be cast by such persons if the vote is not cast on behalf of a person who is excluded from voting on Resolution 12 and:

(i) the person is appointed as a proxy that specifies the way the proxy is to vote on Resolutions 12; or

(ii) the person is the Chairperson and the appointment of the Chairperson as proxy does not specify the way the proxy is to vote on Resolution 12 but expressly authorises the Chairperson to exercise the proxy even if Resolution 12 is connected with the remuneration of a member of the Key Management Personnel.

2.3 Attendance at Meeting

Shareholders are invited to attend the Meeting in person at the time and place indicated in the Notice. Shareholders may vote by directed proxy in lieu of attending the Meeting in person.

Shareholders can submit any questions in advance of the Meeting by emailing the questions to info@hiremii.com by no later than 5.00pm (AWST) on Tuesday, 25 November 2025.

If it becomes necessary or appropriate to make alternative Meeting arrangements to those detailed in the Notice, Shareholders will be updated via the ASX announcements platform and on the Company's website at www.hiremii.com.

3 Annual Report

In accordance with section 317(1) of the Corporations Act the Annual Report must be laid before the annual general meeting. There is no requirement for Shareholders to approve the Annual Report.

At the Meeting, Shareholders will be offered the opportunity to:

(a) discuss the Annual Report which is available online at www.hiremii.com;

(b) ask questions about, or comment on, the management of the Company; and

(c) ask the auditor questions about the conduct of the audit and the preparation and content of the Auditor's Report.

In addition to taking questions at the Meeting, written questions to the Chairperson about the management of the Company, or to the Company's auditor about:

(a) the preparation and the content of the Auditor's Report;

(b) the conduct of the audit;

(c) accounting policies of the Company in relation to the preparation of the financial statements; and

(d) the independence of the auditor in relation to the conduct of the audit,

may be submitted by 5.00pm (AWST) on Tuesday, 25 November 2025 to info@hiremii.com.

4 Resolution 1 – Remuneration Report

In accordance with section 250R(2) of the Corporations Act, the Company must put the Remuneration Report to the vote of Shareholders. The Directors' Report contains the Remuneration Report which sets out the remuneration policy for the Company and the remuneration arrangements in place for the executive Directors, specified executives and non-executive Directors.

In accordance with section 250R(3) of the Corporations Act, Resolution 1 is advisory only and does not bind the Directors. If Resolution 1 is not passed, the Directors will not be required to alter any of the arrangements in the Remuneration Report.

Shareholders will have the opportunity to remove the whole Board except the Managing Director if the Remuneration Report receives a 'no' vote of 25% or more (**Strike**) at two consecutive annual general meetings.

Where a resolution on the Remuneration Report receives a Strike at two consecutive annual general meetings, the Company will be required to put to Shareholders at the second annual general meeting a resolution on whether another meeting should be held (within 90 days) at which all Directors (other than the Managing Director) who were in office at the date of approval of the applicable Directors' Report must stand for re-election.

The Remuneration Report did not receive a Strike at the 2024 annual general meeting. Please note if the Remuneration Report receives a Strike at this Meeting and if a second Strike is received at the 2026 annual general meeting, this may result in the re-election of the Board.

The Chairperson will allow reasonable opportunity for Shareholders to ask questions about or comment on the Remuneration Report.

Resolution 1 is a non-binding resolution.

The Chairperson intends to exercise all available proxies in favour of Resolution 1.

If the Chairperson is appointed as your proxy and you have not specified the way the Chairperson is to vote on Resolution 1, by signing and returning the Proxy Form, you are considered to have provided the Chairperson with an express authorisation for the Chairperson to vote the proxy in accordance with the Chairperson's intention, even though Resolution 1 is connected directly or indirectly with the remuneration of a member of the Key Management Personnel.

5 Resolution 2 – Re-election of Mr David Buckingham as Director

5.1 General

In accordance with Listing Rule 14.5, an entity which has directors must hold an election of directors at each annual general meeting.

Mr David Buckingham was appointed as a Director on 3 May 2021 and was re-elected as a Director on 28 November 2023.

Article 7.3(c) of the Constitution requires one third of all Directors (rounded down to the nearest whole number) to retire at each annual general meeting.

Article 7.3(f) of the Constitution states that a Director who retires under article 7.3(c) of the Constitution is eligible for re-election.

Resolution 2 provides that, pursuant to and in accordance with Listing Rule 14.5, article 7.3(c) of the Constitution and for all other purposes, David Buckingham, Director, retires and being eligible, is re-elected as a Director.

Mr Buckingham is currently the independent non-executive chairman of Hiremii. He has over thirty years of experience as a corporate leader in telecommunications, media, technology, IT and education. Mr Buckingham began his career in the Audit and Corporate Finance team at PricewaterhouseCoopers in the UK and Australia. Most recently, Mr Buckingham served as both Chief Executive Officer and Chief Financial Officer of Navitas Limited (ASX:NVT), a global education provider with over 120 colleges and campuses across 31 countries. Prior to Navitas, David worked for Telewest Global as the Group Treasurer and Director of Financial Planning, Virginmedia, as Finance Director Business Division and iiNet (ASX:IIN) where he held the roles of chief financial officer and chief executive officer between 2008 and 2015.

Mr Buckingham is currently the non-executive chairman of Pentanet Limited (ASX:5GG).

If Resolution 2 is passed, Mr Buckingham will be re-elected and will continue to act as a Director.

If Resolution 2 is not passed, Mr Buckingham will not be re-elected and will cease to act as a Director.

Resolution 2 is an ordinary resolution.

The Chairperson intends to exercise all available proxies in favour of Resolution 2.

5.2 Board Recommendation

Based on Mr Buckingham's skills and significant experience, the Board (excluding Mr Buckingham) supports the re-election of Mr Buckingham and recommends that Shareholders vote in favour of Resolution 2.

6 Resolution 3 – Approval of 10% Placement Facility

6.1 General

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of Equity Securities that a listed company can issue without the approval of its shareholders over any 12 month period to 15% of the fully paid ordinary securities it had on issue at the start of that period (**15% Placement Capacity**).

Listing Rule 7.1A enables an Eligible Entity (term defined below) to issue Equity Securities up to 10% of its issued share capital through placements over a 12 month period after the annual general meeting (**10% Placement Facility**). The 10% Placement Facility is in addition to the Company's 15% Placement Capacity under Listing Rule 7.1.

An eligible entity for the purposes of Listing Rule 7.1A, is an entity that is not included in the S&P/ASX 300 Index and has a market capitalisation of $300 million or less (**Eligible Entity**). The Company is an Eligible Entity as it is not included in the S&P/ASX 300 Index and has a market capitalisation of approximately $8 million (based on the number of Shares on issue and the closing price of Shares on the ASX on 18 September 2025).

Pursuant to Resolution 3, the Company is seeking Shareholder approval to issue Equity Securities under the 10% Placement Facility. The number of Equity Securities to be issued under the 10% Placement Facility will be determined in accordance with the formula prescribed in Listing Rule 7.1A.2 (refer to Section 6.2(c)).

If Resolution 3 is passed, the Company will be able to issue Equity Securities under Listing Rule 7.1A up to 10% of its issued share capital over a 12 month period after the annual general meeting, in addition to the Company’s 15% Placement Capacity under Listing Rule 7.1.

If Resolution 3 is not passed, the Company will not be able to access the 10% Placement Facility to issue Equity Securities without Shareholder approval provided for in Listing Rule 7.1A and will remain subject to the 15% Placement Capacity under Listing Rule 7.1.

Resolution 3 is a special resolution and therefore requires approval of 75% of the votes cast by Shareholders present and eligible to vote (in person, by proxy, by attorney or, in the case of a corporate Shareholder, by a corporate representative).

The Chairperson intends to exercise all available proxies in favour of Resolution 3.

6.2 Listing Rule 7.1A

(a) **Shareholder approval**

The ability to issue Equity Securities under the 10% Placement Facility is subject to Shareholder approval by way of a special resolution at an annual general meeting.

(b) **Equity Securities**

Any Equity Securities issued under the 10% Placement Facility must be in the same class as an existing quoted class of Equity Securities of the Company.

The Company, as at the date of the Notice, has on issue one quoted class of Equity Securities, being Shares.

(c) **Formula for calculating 10% Placement Facility**

Listing Rule 7.1A.2 provides that Eligible Entities which have obtained Shareholder approval at an annual general meeting may issue or agree to issue, during the 12 month period after the date of the annual general meeting, a number of Equity Securities calculated in accordance with the following formula:

(A x D) – E

A is the number of Shares on issue at the commencement of the relevant period:

(A) plus the number of Shares issued in the relevant period under an exception in Listing Rule 7.2 other than exception 9, 16 or 17;

(B) plus the number of Shares issued in the relevant period on the conversion of convertible securities within Listing Rule 7.2 exception 9 where:

(I) the convertible securities were issued or agreed to be issued before the commencement of the relevant period; or

(II) the issue of, or agreement to issue, the convertible securities was approved, or taken under the Listing Rules to have been approved under Listing Rule 7.1 or 7.4;

(C) plus the number of Shares issued in the relevant period under an agreement to issue securities within Listing Rule 7.2 exception 16 where:

(I) the agreement was entered into before the commencement of the relevant period; or

(II) the agreement was approved, or taken under these rules to have been approved, under Listing Rule 7.1 or 7.4

(D) plus the number of any other Shares issued in the relevant period with approval under Listing Rule 7.1 or 7.4;

(E) plus the number of partly paid ordinary shares that became fully paid in the relevant period; and

(F) less the number of Shares cancelled in the relevant period.

Note that A is has the same meaning in Listing Rule 7.1 when calculating an entity's 15% Placement Capacity.

D is 10%

E is the number of Equity Securities issued or agreed to be issued under Listing Rule 7.1A.2 in the 12 months before the date of the issue where the issue or agreement has not been subsequently approved by Shareholders under Listing Rule 7.4.

(d) **Listing Rule 7.1 and Listing Rule 7.1A**

The ability of an entity to issue Equity Securities under Listing Rule 7.1A is in addition to the entity's 15% Placement Capacity under Listing Rule 7.1.

At the date of the Notice, the Company has on issue 151,072,424 Shares and therefore has a capacity to issue:

(i) 22,660,863 Equity Securities under Listing Rule 7.1; and

(ii) subject to Shareholder approval being sought under Resolution 3, 15,107,242 Equity Securities under Listing Rule 7.1A.

The actual number of Equity Securities that the Company will have capacity to issue under Listing Rule 7.1A will be calculated at the date of issue of the Equity Securities in accordance with the formula prescribed in Listing Rule 7.1A.2 (refer to Section 6.2(c)).

(e) **Minimum Issue Price**

The issue price of Equity Securities issued under Listing Rule 7.1A must be not less than 75% of the VWAP of Equity Securities in the same class calculated over the 15 Trading Days on which trades in that class were recorded immediately before:

(i) the date on which the price at which the Equity Securities are to be issued is agreed; or

(ii) if the Equity Securities are not issued within 10 Trading Days of the date in paragraph 6.2(e)(i) above, the date on which the Equity Securities are issued.

(f) **10% Placement Period**

Shareholder approval of the 10% Placement Facility under Listing Rule 7.1A is valid from the date of the annual general meeting at which the approval is obtained and expires on the earlier to occur of:

(i) the date that is 12 months after the date of the annual general meeting at which the approval is obtained;

(ii) the date of the entity's next annual general meeting; or

(iii) the date of Shareholder approval of a transaction under Listing Rules 11.1.2 (a significant change to the nature or scale of activities) or 11.2 (disposal of main undertaking),

(the **10% Placement Period**).

6.3 Effect of Resolution

The effect of Resolution 3 will be to allow the Directors to issue the Equity Securities under Listing Rule 7.1A during the 10% Placement Period without using the Company's 15% Placement Capacity under Listing Rule 7.1.

6.4 Specific information required by Listing Rule 7.3A

In accordance with Listing Rule 7.3A, information is provided as follows:

(a) The Equity Securities will be issued at an issue price of not less than 75% of the VWAP for the Company's Equity Securities over the 15 Trading Days on which trades in that class were recorded immediately before:

(i) the date on which the price at which the Equity Securities are to be issued is agreed; or

(ii) if the Equity Securities are not issued within 10 Trading Days of the date in paragraph 6.4(a)(i) above, the date on which the Equity Securities are issued.

(b) If Resolution 3 is approved by Shareholders and the Company issues Equity Securities under the 10% Placement Facility, the existing Shareholders' voting power in the Company and economic dilution will be diluted as shown in the below table (in the case of listed Options, only if the listed Options are exercised). There is a risk that:

(i) the market price for the Company's Equity Securities may be significantly lower on the date of the issue of the Equity Securities than on the date of the Meeting; and

(ii) the Equity Securities may be issued at a price that is at a discount to the market price for the Company's Equity Securities on the issue date,

which may have an effect on the amount of funds raised by the issue of the Equity Securities.

(c) The below table shows the dilution of existing Shareholders on the basis of the current market price of Shares and the current number of ordinary securities for variable 'A' calculated in accordance with the formula in Listing Rule 7.1A.2 as at the date of the Notice.

(d) The table also shows:

(i) two examples where variable 'A' has increased, by 50% and 100%. Variable 'A' is based on the number of ordinary securities the Company has on issue. The number of ordinary securities on issue may increase as a result of issues of ordinary securities that do not require Shareholder approval (for example, a pro rata entitlements issue or scrip issued under a takeover offer) or future specific placements under Listing Rule 7.1 that are approved at a future Shareholders' meeting; and

(ii) two examples of where the issue price of ordinary securities has decreased by 50% and increased by 50% as against the current market price.

Variable 'A' in Listing Rule 7.1A.2		**Dilution**		
		$0.025 **50% decrease in Issue Price**	**$0.06** **Issue Price**	**$0.075** **50% increase in Issue Price**
Current Variable A **151,072,424 Shares**	**10% Voting Dilution**	15,107,242 Shares	15,107,242 Shares	15,107,242 Shares
	Funds raised	$453,217	$906,435	$1,812,869

50% increase in current Variable A **226,608,636 Shares**	**10% Voting Dilution**	22,660,864 Shares	22,660,864 Shares	22,660,864 Shares
	Funds raised	$679,826	$1,359,652	$2,719,304
100% increase in current Variable A **302,144,848 Shares**	**10% Voting Dilution**	30,214,485 Shares	30,214,485 Shares	30,214,485 Shares
	Funds raised	$906,435	$1,812,869	$3,625,738

The table has been prepared on the following assumptions:

(i) the Company issues the maximum number of Equity Securities available under the 10% Placement Facility;

(ii) no Options (including any Options issued under the 10% Placement Facility) or Performance Rights are exercised into Shares before the date of the issue of the Equity Securities;

(iii) the 10% voting dilution reflects the aggregate percentage dilution against the issued share capital at the time of issue. This is why the voting dilution is shown in each example as 10%;

(iv) the table does not show an example of dilution that may be caused to a particular Shareholder by reason of placements under the 10% Placement Facility, based on that Shareholder's holding at the date of the Meeting;

(v) the table shows only the effect of issues of Equity Securities under Listing Rule 7.1A, not under the 15% Placement Capacity under Listing Rule 7.1;

(vi) the issue of Equity Securities under the 10% Placement Facility consists only of Shares; and

(vii) the issue price is $0.06, being the closing price of Shares on ASX on 13 October 2025.

(e) The Company will only issue the Equity Securities during the 10% Placement Period. The approval under Resolution 3 for the issue of the Equity Securities will cease to be valid on the earlier of:

(i) the date that is 12 months after the date of the annual general meeting at which the approval is obtained;

(ii) the time and date of the entity's next annual general meeting; or

(iii) the time and date that Shareholders approve a transaction under Listing Rule 11.1.2 (a significant change to the nature or scale of activities) or Listing Rule 11.2 (disposal of main undertaking).

(f) The Company may seek to issue the Equity Securities for cash consideration. In such circumstances, the Company intends to use the funds raised towards the expansion of the Company's business and/or general working capital.

(g) The Company will comply with the disclosure obligations under Listing Rules 3.10.3 and 7.1A.4 upon issue of any Equity Securities.

(h) The Company's allocation policy is dependent on the prevailing market conditions at the time of any proposed issue pursuant to the 10% Placement Facility. The identity of the subscribers of Equity Securities will be determined on a case-by-case basis having regard to the factors including but not limited to the following:

(i) the methods of raising funds that are available to the Company, including but not limited to, rights issue or other issues in which existing security holders can participate;

(ii) the effect of the issue of the Equity Securities on the control of the Company;

(iii) the financial situation and solvency of the Company; and

(iv) advice from corporate, financial and broking advisers (if applicable).

(i) The subscribers under the 10% Placement Facility have not been determined as at the date of the Notice but may include existing substantial Shareholders and/or new Shareholders who are not a related party or an associate of a related party of the Company.

(j) Further, if the Company is successful in acquiring new assets or investments, it is likely that the subscribers under the 10% Placement Facility will be the vendors of the new assets or investments.

(k) In the 12 months preceding the date of the Meeting, the Company has issued a total of 13,690,475 Equity Securities under Listing Rule 7.1A.2, which represents approximately 9.3% of the total number of Equity Securities on issue at 27 November 2024.

Date of issue	Issued to, or basis of issue	Equity Securities issued	Issue price per Equity Security	Discount of issue price to closing market price on date of agreement	Total cash consideration, amount of cash spent and use of funds, or intended use of funds for remaining cash
Issued on 21 October 2025	13,690,475 Shares, being the Tranche 1 Placement Shares, were issued to professional and sophisticated investors identified by the Company and the Joint Lead Managers through a bookbuild process. The issue of the Equity Securities under Listing Rule 7.1A.2 raised proceeds of $575,000 (before costs).	Fully paid ordinary Shares	$0.042	30% discount to the closing price of Shares on 6 October 2025.	As at the date of the Notice, the Company has not utilised the proceeds raised from the issue of the Tranche 1 Placement Shares, however intends to use the proceeds for general working purposes and to assist the Company to accelerate the commercialisation of the Hiremii platform, advance customer-driven enhancements and AI-led optimisation initiatives, and to pursue strategic acquisition opportunities that complement and extend the Company's technology and core business.

(l) The Company previously obtained Shareholder approval under Listing Rule 7.1A at its annual general meeting held on 30 October 2024.

(m) A voting exclusion statement is included in the Notice for Resolution 3.

(n) At the date of the Notice, the Company is not proposing to make an issue of the Equity Securities and has not approached any particular existing Shareholder or security holder or an identifiable class of existing security holder to participate in the issue of the Equity Securities. No existing Shareholder's votes will therefore be excluded under the voting exclusion in the Notice.

6.5 Board Recommendation

The Board recommends that Shareholders vote in favour of Resolution 3.

7 Resolution 4 – Ratification of T1 Placement Shares issued under Listing Rule 7.1A

7.1 Background

(a) Capital Raising

On 10 October 2025, the Company announced it had received firm commitments from professional and sophisticated investors to raise $650,000 (before costs) via a two-tranche placement (**Placement**). It is proposed that Directors, Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien will participate in the Placement subject to Shareholder approval.

The Placement involves the issue of 15,476,189 fully paid ordinary Shares at an issue price of $0.042 per Share. In addition, each participant (and/or their nominee(s)) will be entitled to one (1) free attaching Option for every one (1) Placement Share that the participant subscribes for, each with an exercise price of $0.05, expiring two years from the date of issue and having the terms and conditions contained in Schedule 2 (**Placement Options**).

The Placement comprises:

(i) 13,690,475 Shares (**Tranche 1 Placement Shares**) under Listing Rule 7.1A and 13,690,475 Placement Options (**Tranche 1 Placement Options**) under Listing Rule 7.1, to institutional and sophisticated investors, which were issued on Tuesday, 21 October 2025, to raise $575,000 (before costs) (**Tranche 1 Placement**); and

(ii) the issue of 1,785,714 Shares (**Tranche 2 Placement Shares**) and 1,785,714 Placement Options (**Tranche 2 Placement Options**) under Listing Rule 10.11, to Directors, Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien, to raise $75,000 (before costs), subject to Shareholder approval under Resolutions 6 to 11 (inclusive) (**Tranche 2 Placement**).

Bay Financial and Sequoia Corporate Finance acted as the joint lead managers to the Placement (**Joint Lead Managers**).

(b) Use of Funds

Proceeds from the Placement will be utilised for general working purposes and to assist the Company to accelerate the commercialisation of the Hiremii platform, advance customer-driven enhancements and AI-led optimisation initiatives, and to pursue strategic acquisition opportunities that complement and extend the Company's technology and core business.

(c) Capital Structure

The capital structure of the Company on completion of the Placement will be as follows:

	Shares	Options	Performance Rights
Securities on issue as at the date of the Notice	164,762,899	21,523,808	6,534,211
Securities to be issued under the Tranche 2 Placement (Subject to Shareholder approval)	1,785,714	1,785,714	-
TOTAL	**166,548,613**	**23,309,522**	**6,534,211**

Notes:

1. The above table assumes that no existing Options or Performance Rights are exercised or converted.
2. The above table does not include the number of Shares that the Company is proposing to issue under Resolution 12. Refer to Section 11 for details.

7.2 General

Resolution 4 seeks Shareholder approval pursuant to Listing Rule 7.4 to ratify the issue of the Tranche 1 Placement Shares issued pursuant to the Company's 10% Placement Facility under Listing Rule 7.1A.

Resolution 4 is an ordinary resolution.

The Chairperson intends to exercise all available undirected proxies in favour of Resolution 4.

7.3 Listing Rules 7.1 and 7.1A

Refer to Section 6.1 for a summary of Listing Rules 7.1 and 7.1A.

Listing Rule 7.4 provides that if the Company in a general meeting ratifies the previous issue of Equity Securities made pursuant to Listing Rule 7.1 or Listing Rule 7.1A (and provided that the previous issue did not breach Listing Rule 7.1 or Listing Rule 7.1A) those Equity Securities will be deemed to have been made with Shareholder approval for the purpose of Listing Rule 7.1 or Listing Rule 7.1A.

The issue of the Tranche 1 Placement Shares does not fit within any of the exceptions to Listing Rule 7.1A and, as it has not been approved by Shareholders, it effectively uses up part of the Company's 10% Placement Facility, thereby reducing the Company’s capacity to issue further Equity Securities without Shareholder approval under Listing Rule 7.1A for the 12-month period following the issue of the Tranche 1 Placement Shares.

The Company wishes to retain as much flexibility as possible to issue additional Equity Securities into the future up to the 10% Placement Facility set out in Listing Rule 7.1A without the requirement to obtain prior Shareholder approval.

If Resolution 4 is passed, the Tranche 1 Placement Shares will be excluded in calculating the Company's 10% Placement Facility in Listing Rule 7.1A, effectively increasing the number of Equity Securities it can issue without Shareholder approval over the 12-month period following the issue of the Tranche 1 Placement Shares.

If Resolution 4 is not passed, the Tranche 1 Placement Shares will be included in calculating the Company's 10% Placement Facility in Listing Rule 7.1A, effectively decreasing the number of Equity Securities it can issue without Shareholder approval over the 12-month period following the issue of the Tranche 1 Placement Shares.

7.4 Specific information required by Listing Rule 7.5

The following information in relation to Resolution 4 is provided to Shareholders for the purposes of Listing Rule 7.5.

(a) The Tranche 1 Placement Shares were issued to professional and sophisticated investors identified by the Company and the Joint Lead Managers through a bookbuild process. No investor under the Tranche 1 Placement was a related party, a member of the Company's Key Management Personnel or an adviser of the Company or an associate of any of those persons. Mr Jason Carroll, a substantial Shareholder, participated in the Tranche 1 Placement and will receive more than 1% of the Company's current issued share capital under the Tranche 1 Placement.

(b) The Tranche 1 Placement Shares comprised the issue of 13,690,475 Shares under Listing Rule 7.1A.

(c) The Tranche 1 Placement Shares are fully paid ordinary Shares and rank equally in all respects with the Company's existing Shares.

(d) The Tranche 1 Placement Shares were issued at an issue price of $0.042 per Share, raising a total of $575,000 (before costs).

(e) The Tranche 1 Placement Shares were issued on Tuesday, 21 October 2025.

(f) Funds raised from the issue of the Tranche 1 Placement Shares are intended to be utilised as detailed in Section 7.1.

(g) The Tranche 1 Placement Shares were issued pursuant to subscription letters pursuant to which the participants subscribed for the Tranche 1 Placement Shares at an issue price of $0.042 per Share and one (1) free attaching Tranche 1 Placement Option for every one (1) Tranche 1 Placement Share subscribed for by the holder. The subscription letters contain terms that are customary for an agreement of this nature.

(h) A voting exclusion statement is included in the Notice for Resolution 4.

7.5 Board recommendation

The Board recommends that Shareholders vote in favour of Resolution 4.

8 Resolution 5 – Ratification of T1 Placement Options issued under Listing Rule 7.1

8.1 General

Refer to Section 7.1 for details on the Tranche 1 Placement.

Resolution 5 seeks Shareholder approval pursuant to Listing Rule 7.4 to ratify the issue of the Tranche 1 Placement Options issued pursuant to the Company's 15% Placement Capacity under Listing Rule 7.1.

Resolution 5 is an ordinary resolution.

The Chairperson intends to exercise all available undirected proxies in favour of Resolution 5.

8.2 Listing Rules 7.1 and 7.1A

Refer to Section 6.1 for a summary of Listing Rules 7.1 and 7.1A.

Listing Rule 7.4 provides that if the Company in a general meeting ratifies the previous issue of Equity Securities made pursuant to Listing Rule 7.1 or Listing Rule 7.1A (and provided that the previous issue did not breach Listing Rule 7.1 or Listing Rule 7.1A) those Equity Securities will be deemed to have been made with Shareholder approval for the purpose of Listing Rule 7.1 or Listing Rule 7.1A.

The issue of the Tranche 1 Placement Options does not fit within any of the exceptions to Listing Rule 7.1 and, as it has not been approved by Shareholders, it effectively uses up part of the Company's 15% Placement Capacity, thereby reducing the Company's capacity to issue further Equity Securities without Shareholder approval under Listing Rule 7.1 for the 12-month period following the issue of the Tranche 1 Placement Options.

The Company wishes to retain as much flexibility as possible to issue additional Equity Securities into the future up to the 15% Placement Capacity set out in Listing Rule 7.1 without the requirement to obtain prior Shareholder approval.

If Resolution 5 is passed, the Tranche 1 Placement Options will be excluded in calculating the Company's 15% Placement Capacity in Listing Rule 7.1, effectively increasing the number of Equity Securities it can issue without Shareholder approval over the 12-month period following the issue of the Tranche 1 Placement Options.

If Resolution 5 is not passed, the Tranche 1 Placement Options will be included in calculating the Company's 15% Placement Capacity in Listing Rule 7.1, effectively decreasing the number of Equity Securities it can issue without Shareholder approval over the 12-month period following the issue of the Tranche 1 Placement Options.

8.3 Specific information required by Listing Rule 7.5

The following information in relation to Resolution 5 is provided to Shareholders for the purposes of Listing Rule 7.5.

(a) The Tranche 1 Placement Options were issued to professional and sophisticated investors identified by the Company and the Joint Lead Managers through a bookbuild process. No investor under the Tranche 1 Placement was a related party, a member of the Company's Key Management Personnel or an adviser of the Company or an associate of any of those persons. Mr Jason Carroll, a substantial Shareholder, participated in the Tranche 1 Placement and will receive more than 1% of the Company's current issued share capital under the Tranche 1 Placement.

(b) The Tranche 1 Placement Options comprised the issue of 13,690,475 Options under Listing Rule 7.1.

(c) The Tranche 1 Placement Options have an exercise price of $0.05 each and expire 2 years from the date of issue. Refer to in Schedule 2 for the terms and conditions of the Tranche 1 Placement Options.

(d) The Tranche 1 Placement Options were agreed to be issued for nil cash consideration, as they are free attaching on the basis of one (1) free attaching Tranche 1 Placement Option for every one (1) Tranche 1 Placement Share subscribed for by the holder.

(e) The Shares to be issued on exercise of the Tranche 1 Placement Options will be fully paid ordinary Shares and rank equally in all respects with the Company's existing Shares.

(f) The Tranche 1 Placement Options were issued on Tuesday, 21 October 2025.

(g) The Tranche 1 Placement Options were issued in connection with the Placement. The purpose of the Placement is to raise funds to be utilised as detailed in Section 7.1.

(h) The Tranche 1 Placement Options were issued pursuant to subscription letters pursuant to which the participants subscribed for the Tranche 1 Placement Shares at an issue price of $0.042 per Share and one (1) free attaching Tranche 1 Placement Option for every one (1) Tranche 1 Placement Share subscribed for by the holder. The subscription letters contain terms that are customary for an agreement of this nature.

(i) A voting exclusion statement is included in the Notice for Resolution 5.

8.4 Board recommendation

The Board recommends that Shareholders vote in favour of Resolution 5.

9 Resolutions 6, 8 and 10 – Issue of Tranche 2 Placement Shares to Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien

9.1 General

Resolutions 6, 8 and 10 seek Shareholder approval pursuant to and in accordance with Listing Rule 10.11, Chapter 2E of the Corporations Act (including section 208 of the Corporations Act) (and for all other purposes) to issue (in aggregate) 1,785,714 Shares to certain Directors, being Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien (and/or their respective nominee(s)) under the Tranche 2 Placement. The Tranche 2 Placement Shares will be offered at the same issue price as the Tranche 1 Placement Shares under the Placement (being $0.042 per Share), to raise up to $75,000 (before costs).

Refer to Section 7.1 for further details of the Placement.

The Company is proposing to issue:

(a) 833,333 Shares to Mr Andrew Hornby (and/or his nominee(s)) pursuant to Resolution 6;

(b) 714,286 Shares to Ms Sophie Chen (and/or her nominee(s)) pursuant to Resolution 8; and

(c) 238,095 Shares to Mr Conor O'Brien (and/or his nominee(s)) pursuant to Resolution 10.

In accordance with Listing Rule 10.11, Shareholder approval is required for the issue of Shares to a related party. Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien are each Directors and therefore are related parties of the Company.

The issues of the relevant Tranche 2 Placement Shares does not fall within any of the exceptions to Listing Rule 10.11 and are therefore conditional upon Shareholder approval (which is being sought pursuant to Resolutions 6, 8 and 10).

Resolutions 6, 8 and 10 are ordinary resolutions.

The Chairperson intends to exercise all available proxies in favour of Resolutions 6, 8 and 10.

9.2 Chapter 2E of the Corporations Act

Chapter 2E of the Corporations Act requires that for a public company, or an entity that the public company controls, to give a financial benefit to a related party of the public company, the public company or entity must:

(a) obtain the approval of the public company's members in the manner set out in sections 217 to 227 of the Corporations Act; and

(b) give the benefit within 15 months following such approval, unless the giving of the financial benefit falls within an exception set out in sections 210 to 216 of the Corporations Act.

Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien are Directors and therefore are related parties of the Company for the purposes of section 208 of the Corporations Act.

There is no quorum of the Board capable forming the view that the exception for dealing on arm's length terms in section 210 of the Corporations Act applies, due to Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien having an interest in the outcome of Resolutions 6, 8 and 10. Accordingly, the Board has determined to seek Shareholder approval pursuant to section 208 of the Corporations Act for Resolutions 6, 8 and 10.

9.3 Listing Rule 10.11

Listing Rule 10.11 provides that unless one of the exceptions in Listing Rule 10.12 applies, a listed company must not issue or agree to issue Equity Securities to:

(a) a related party;

(b) a person who is, or was at any time in the six months before the issue or agreement, a substantial (30%+) holder in the company;

(c) a person who is, or was at any time in the six months before the issue or agreement, a substantial (10%+) holder in the company and who has nominated a director to the board of the company pursuant to a relevant agreement which gives them a right or expectation to do so;

(d) an associate of a person referred to in (a) to (c); or

(e) a person whose relationship with the company or a person referred to in (a) to (d) is such that, in ASX's opinion, the issue or agreement should be approved by its shareholders,

unless it obtains shareholder approval.

The issue of the Tranche 2 Placement Shares to Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien (and/or their respective nominee(s)) falls within paragraph (a) above (being Listing Rule 10.11.1), as Mr Hornby, Ms Chen and Mr O'Brien are related parties of the Company, and does not fall within any of the exceptions in Listing Rule 10.12. It therefore requires the approval of Shareholders under Listing Rule 10.11.

Resolution 6 seeks the required Shareholder approval to issue 833,333 Shares to Mr Andrew Hornby (and/or his nominee(s)) under and for the purposes of Listing Rule 10.11 (and for all other purposes).

Resolution 8 seeks the required Shareholder approval to issue 714,286 Shares to Ms Sophie Chen (and/or her nominee(s)) under and for the purposes of Listing Rule 10.11 (and for all other purposes).

Resolution 10 seeks the required Shareholder approval to issue 238,095 Shares to Mr Conor O'Brien (and/or his nominee(s)) under and for the purposes of Listing Rule 10.11 (and for all other purposes).

If Resolution 6, 8 or 10 is passed, the Company will be able to proceed with the issue of the relevant Tranche 2 Placement Shares to the relevant Director (and/or their respective nominee(s)) and pursuant to Listing Rule 7.2 (exception 14), the issue of the relevant Tranche 2 Placement Shares will be excluded from the calculation of the number of Equity Securities that the Company can issue without Shareholder approval under Listing Rule 7.1.

If Resolution 6, 8 or 10 is not passed, the Company will not be able to proceed with the issue of the relevant Tranche 2 Placement Shares to the relevant Director (and/or their respective nominee(s)), and the Company will not be able to raise funds from issuing Tranche 2 Placement Shares to that Director and may seek to raise them from alternate investors.

9.4 Information required by Listing Rule 10.13 and section 219 of the Corporations Act

The following information in relation to Resolutions 6, 8 and 10 is provided to Shareholders for the purposes of Listing Rule 10.13 and section 219 of the Corporations Act:

(a) The Tranche 2 Placement Shares under the Tranche 2 Placement will be issued to:

  (i) Mr Andrew Hornby (and/or his nominee(s)) under Resolution 6;

  (ii) Ms Sophie Chen (and/or her nominee(s)) under Resolution 8; and

  (iii) Mr Conor O'Brien (and/or his nominee(s)) under Resolution 10.

(b) Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien fall within Listing Rule 10.11.1 as they are Directors and therefore related parties of the Company.

(c) The maximum number of Tranche 2 Placement Shares to be issued to:

  (i) Mr Andrew Hornby (and/or his nominee(s)) is 833,333 Shares pursuant to Resolution 6;

  (ii) Ms Sophie Chen (and/or her nominee(s)) is 714,286 Shares pursuant to Resolution 8; and

  (iii) Mr Conor O'Brien (and/or his nominee(s)) is 238,095 Shares pursuant to Resolution 10.

(d) The Tranche 2 Placement Shares will be fully paid ordinary Shares and will rank equally in all respects with the Company's existing Shares on issue.

(e) The Tranche 2 Placement Shares will have an issue price of $0.042 per Share, raising a total of up to $75,000 (before costs).

(f) The Tranche 2 Placement Shares will be issued no later than one month after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the Listing Rules).

(g) Funds raised from the issue of the Tranche 2 Placement Shares to Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien (and/or their respective nominee(s)) are intended to be utilised as detailed in Section 7.1.

(h) The estimated value of the financial benefit provided to the Directors on the basis of the issue price per Share under the Tranche 2 Placement (being $0.042 per Share) is as follows:

Director	Number of Tranche 2 Placement Shares	Value at $0.042 per Share
Mr Andrew Hornby	833,333	$35,000
Ms Sophie Chen	714,286	$30,000
Mr Conor O'Brien	238,095	$10,000

(i) The current remuneration package of the Directors, being Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien is as follows:

Director[1]	Cash salary and fees ($)	Cash bonus[2] ($)	Non-monetary ($)	Superannuation ($)	Share based payments ($)	Total ($)
Mr Andrew Hornby	285,000	21,554	-	33,529	24,032	**364,115**
Ms Sophie Chen[3]	-	-	-	5,405	45,045	**50,450**
Mr Conor O'Brien	40,000		-	4,600	-	**44,600**

Notes:

1. Remuneration for the financial year ended 30 June 2025.
2. FY24 bonus paid during the year ended 30 June 2025 based on the performance against KPIs approved by the Board.
3. Ms Sophie Chen was appointed as a non-executive Director on 31 October 2024. Ms Chen's remuneration package is for the period 31 October 2024 to 30 June 2025. The issue of Shares was approved by Shareholders at the Company's general meeting on 15 September 2025.

(j) As at the date of the Notice, Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien's interests in the securities of the Company are as follows:

Director	Shares	Options	Performance Rights
Mr Andrew Hornby	6,260,188[1]	1,000,000[4]	461,440
Ms Sophie Chen[2]	-	-	-
Mr Conor O'Brien	6,728,429[3]	-	-

Notes:

1. If Resolution 6 is passed, Mr Hornby will have an interest in a further 833,333 Shares.
2. If Resolution 8 is passed, Ms Chen will have an interest in a further 714,286 Shares.
3. If Resolution 10 is passed, Mr O'Brien will have an interest in a further 238,095 Shares.
4. Options exercisable at $0.101 on or before 13 December 2025.

(k) The Tranche 2 Placement Shares to be issued to Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien (and/or their respective nominee(s)), will result in a dilution of all other Shareholders' holdings in the Company of 1.1% based on the issued Shares as at the date of the Notice and 0.9% on a fully diluted basis.

(l) The historical quoted price information for Shares for the last twelve months from the date of the Notice is as follows:

Shares	Price	Date
Highest	$0.06	3 October 2025
Lowest	$0.04	19 September 2025
Last	$0.06	14 October 2025

(m) The Tranche 2 Placement Shares are to be offered pursuant to short form subscription letters pursuant to which Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien (and/or their respective nominee(s)) will subscribe for Shares at an issue price of $0.042 per Share, and one (1) free attaching Tranche 2 Placement

Option for every one (1) Tranche 2 Placement Share subscribed for by the respective Director. The subscription letters contain terms that are customary for an agreement of this nature.

(n) Mr Andrew Hornby has an interest in Resolution 6 and therefore believes it inappropriate to make a recommendation.

(o) Ms Sophie Chen has an interest in Resolution 8 and therefore believes it inappropriate to make a recommendation.

(p) Mr Conor O'Brien has an interest in Resolution 10 and therefore believes it inappropriate to make a recommendation.

(q) A voting exclusion statement is included in the Notice for Resolutions 6, 8 and 10.

(r) Other than the information above and otherwise detailed in the Notice, the Company believes there is no there is no other information that would be reasonably required by Shareholders to pass Resolutions 6, 8 and 10.

9.5 Director Recommendation

The Directors (excluding Mr Andrew Hornby, due to his personal interest in Resolution 6) recommend that Shareholders vote in favour of Resolution 6.

The Directors (excluding Ms Sophie Chen, due to his personal interest in Resolution 8) recommend that Shareholders vote in favour of Resolution 8.

The Directors (excluding Mr Conor O'Brien, due to his personal interest in Resolution 10) recommend that Shareholders vote in favour of Resolution 10.

10 Resolutions 7, 9 and 11 – Issue of Tranche 2 Placement Options to Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien

10.1 General

Resolutions 7, 9 and 11 seek Shareholder approval pursuant to and in accordance with Listing Rule 10.11, Chapter 2E of the Corporations Act (including section 208 of the Corporations Act) (and for all other purposes) to issue (in aggregate) 1,785,714 Options to certain Directors, being Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien (and/or their respective nominee(s)) under the Tranche 2 Placement. Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien (and/or their respective nominee(s)) will be entitled to one (1) free attaching Tranche 2 Placement Option for every one (1) Tranche 2 Placement Share that the Director subscribed for, each with an exercise price of $0.05 and expiring two years from the date of issue.

Refer to Section 7.1 for further details of the Placement.

The Company is proposing to issue:

(a) 833,333 Options to Mr Andrew Hornby (and/or his nominee(s)) pursuant to Resolution 7;

(b) 714,286 Options to Ms Sophie Chen (and/or her nominee(s)) pursuant to Resolution 9; and

(c) 238,095 Options to Mr Conor O'Brien (and/or his nominee(s)) pursuant to Resolution 11.

The terms and conditions of the Tranche 2 Placement Options to be issued to the Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien (and/or their respective nominee(s)) are summarised in Schedule 2.

In accordance with Listing Rule 10.11, Shareholder approval is required for the issue of Options to a related party. Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien are each Directors and therefore are related parties of the Company.

The issues of the relevant Tranche 2 Placement Shares does not fall within any of the exceptions to Listing Rule 10.11 and are therefore conditional upon Shareholder approval (which is being sought pursuant to Resolutions 7, 9 and 11).

Resolutions 7, 9 and 11 are ordinary resolutions.

Resolutions 7 is conditional on the passing of Resolution 6.

Resolutions 9 is conditional on the passing of Resolution 8.

Resolutions 11 is conditional on the passing of Resolution 10.

The Chairperson intends to exercise all available proxies in favour of Resolutions 7, 9 and 11.

10.2 Chapter 2E of the Corporations Act

Refer to Section 9.2 for a summary of Chapter 2E of the Corporations Act.

Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien are Directors and therefore are related parties of the Company for the purposes of section 208 of the Corporations Act.

There is no quorum of the Board capable forming the view that the exception for dealing on arm's length terms in section 210 of the Corporations Act applies, due to Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien having an interest in the outcome of Resolutions 7, 9 and 11. Accordingly, the Board has determined to seek Shareholder approval pursuant to section 208 of the Corporations Act for Resolutions 7, 9 and 11.

10.3 Listing Rule 10.11

Refer to Section 9.3 for a summary of Listing Rule 10.11.

The issue of the Tranche 2 Placement Options to Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien (and/or their respective nominee(s)) falls within paragraph (a) above (being Listing Rule 10.11.1), as Mr Hornby, Ms Chen and Mr O'Brien are related parties of the Company, and does not fall within any of the exceptions in Listing Rule 10.12. It therefore requires the approval of Shareholders under Listing Rule 10.11.

Resolution 7 seeks the required Shareholder approval to issue 833,333 Options to Mr Andrew Hornby (and/or his nominee(s)) under and for the purposes of Listing Rule 10.11 (and for all other purposes).

Resolution 9 seeks the required Shareholder approval to issue 714,286 Options to Ms Sophie Chen (and/or her nominee(s)) under and for the purposes of Listing Rule 10.11 (and for all other purposes).

Resolution 11 seeks the required Shareholder approval to issue 238,095 Options to Mr Conor O'Brien (and/or his nominee(s)) under and for the purposes of Listing Rule 10.11 (and for all other purposes).

If Resolution 7, 9 or 11 is passed, the Company will be able to proceed with the issue of the relevant Tranche 2 Placement Options to the relevant Director (and/or their respective nominee(s)) and pursuant to Listing Rule 7.2 (exception 14), the issue of the relevant Tranche 2 Placement Options will be excluded from the calculation of the number of Equity Securities that the Company can issue without Shareholder approval under Listing Rule 7.1.

If Resolution 7, 9 or 11 is not passed, the Company will not be able to proceed with the issue of the relevant Tranche 2 Placement Options to the relevant Director (and/or their respective nominee(s)).

10.4 Specific information required by Listing Rule 10.13 and section 219 of the Corporations Act

The following information in relation to Resolutions 7, 9 and 11 is provided to Shareholders for the purposes of Listing Rule 10.13 and section 219 of the Corporations Act:

(a) The Tranche 2 Placement Options under the Tranche 2 Placement will be issued to:

 (i) Mr Andrew Hornby (and/or his nominee(s)) under Resolution 7;

 (ii) Ms Sophie Chen (and/or her nominee(s)) under Resolution 9; and

 (iii) Mr Conor O'Brien (and/or his nominee(s)) under Resolution 11.

(b) Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien fall within Listing Rule 10.11.1 as they are related parties of the Company by virtue of being Directors.

(c) The maximum number of Tranche 2 Placement Options to be issued to:

 (i) Mr Andrew Hornby (and/or his nominee(s)) is 833,333 Options pursuant to Resolution 7;

 (ii) Ms Sophie Chen (and/or her nominee(s)) is 714,286 Options pursuant to Resolution 9; and

 (iii) Mr Conor O'Brien (and/or his nominee(s)) is 238,095 Options pursuant to Resolution 11.

(d) The Shares to be issued on exercise of the Tranche 2 Placement Options will be fully paid ordinary Shares in the capital of the Company and will rank equally in all respects with the existing Shares on issue.

(e) The Tranche 2 Placement Options have an exercise price of $0.05 and expire 2 years from the date of issue.

(f) The Tranche 2 Placement Options will be issued no later than one (1) month after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the Listing Rules).

(g) The Tranche 2 Placement Options will be issued for nil consideration as they are being issued as one (1) free attaching Tranche 2 Placement Option for every one (1) Tranche 2 Placement Share subscribed for by the Director. Therefore, no funds will be raised from the issue of the Tranche 2 Placement Options.

(h) Based on a Trinomial Lattice option pricing model, the value of the Tranche 2 Placement Options and determined on the basis of the assumptions detailed below. The value of the Tranche 2 Placement Options is as follows:

	The Tranche 2 Placement Options
Valuation Date	15 October 2025
Market price of Shares	$0.05
Exercise price	$0.05
Interest rate	3.5%

Volatility	78.5%
Expiry date	2 years from issue date
No. of Options	1,785,714
Indicative value	$0.0207 per Option

(i) The terms and conditions of the Tranche 2 Placement Options are detailed in Schedule 2.

(j) The current remuneration package of the Directors, being Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien is as follows:

Director[1]	Cash salary and fees ($)	Cash bonus[2] ($)	Non-monetary ($)	Superannuation ($)	Share based payments ($)	Total ($)
Mr Andrew Hornby	285,000	21,554	-	33,529	24,032	**364,115**
Ms Sophie Chen[2]	-	-	-	5,405	45,045	**50,450**
Mr Conor O'Brien	40,000		-	4,600	-	**44,600**

Notes:

1. Remuneration for the financial year ended 30 June 2025.
2. FY24 bonus paid during the year ended 30 June 2025 based on the performance against KPIs approved by the Board.
3. Ms Sophie Chen was appointed as non-Executive Director on 31 October 2024. Ms Chen's remuneration package is for the period 31 October 2024 to 30 June 2025. The issue of Shares was approved by Shareholders at the Company's general meeting on 15 September 2025.

(k) As at the date of the Notice, Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien's interests in the securities of the Company are as follows:

Director	Shares	Options	Performance Rights
Mr Andrew Hornby	6,260,188[1]	1,000,000[4]	461,440
Ms Sophie Chen[2]	-	-	
Mr Conor O'Brien	6,728,429[3]	-	

Notes:

1. If Resolution 7 is passed, Mr Hornby will have an interest in a further 833,333 Shares.
2. If Resolution 9 is passed, Ms Chen will have an interest in a further 714,286 Shares.
3. If Resolution 11 is passed, Mr O'Brien will have an interest in a further 238,095 Shares.
4. Options exercisable at $0.101 on or before 13 December 2025.

(l) The Tranche 2 Placement Options to be issued to Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien (and/or their respective nominee(s)), assuming that all Tranche 2 Placement Options are exercised, will result in a dilution of all other Shareholders' holdings in the Company of 1.1% based on the issued Shares as at the date of the Notice and 0.9% on a fully diluted basis.

(m) The historical quoted price information for Shares for the last twelve months from the date of the Notice is as follows:

Shares	Price	Date
Highest	$0.06	3 October 2025
Lowest	$0.04	19 September 2025
Last	$0.06	14 October 2025

(n) The Tranche 2 Placement Options are to be offered pursuant to short form subscription letters pursuant to which Mr Andrew Hornby, Ms Sophie Chen and Mr Conor O'Brien (and/or their respective nominee(s)) will subscribe for the Tranche 2 Placement Shares at an issue price of $0.042 per Share, with one (1) free attaching Tranche 2 Placement Option for every one (1) Tranche 2 Placement Share subscribed for by the Director. The subscription letters contain terms that are customary for an agreement of this nature.

(o) Mr Andrew Hornby has an interest in Resolution 7 and therefore believes it inappropriate to make a recommendation.

(p) Ms Sophie Chen has an interest in Resolution 9 and therefore believes it inappropriate to make a recommendation.

(q) Mr Conor O'Brien has an interest in Resolution 11 and therefore believes it inappropriate to make a recommendation.

(r) A voting exclusion statement is included in the Notice for Resolutions 7, 9 and 11.

(s) Other than the information above and otherwise detailed in the Notice, the Company believes there is no there is no other information that would be reasonably required by Shareholders to pass Resolutions 7, 9 and 11.

10.5 Board recommendation

The Directors (excluding Mr Andrew Hornby, due to his personal interest in Resolution 7) recommend that Shareholders vote in favour of Resolution 7.

The Directors (excluding Ms Sophie Chen, due to his personal interest in Resolution 9) recommend that Shareholders vote in favour of Resolution 9.

The Directors (excluding Mr Conor O'Brien, due to his personal interest in Resolution 11.) recommend that Shareholders vote in favour of Resolution 11.

11 Resolution 12 – Issue of Director Shares to Ms Sophie Chen in lieu of Director Fees

11.1 General

In accordance with Listing Rule 10.11 and for all other purposes, Resolution 12 seeks Shareholder approval to issue Shares to non-executive Director, Ms Sophie Chen (and/or her nominee(s)) (**Director Shares**) in lieu of her director fees of $73,197.50, which will accrue from 31 October 2024 to 27 November 2025 (**Director Fees**). The Director Shares will be issued in accordance with the formula in Section 11.4(c).

The Board considers that the issue of Director Shares to Ms Chen (and/or her nominee(s)) will allow the Company to preserve its cash reserves and is a cost effective method to further align the interests of the Directors and the Shareholders.

Resolution 12 is an ordinary resolution.

The Chairperson intends to exercise all available proxies in favour of Resolution 12.

11.2 Chapter 2E of the Corporations Act

Refer to Section 9.2 for a summary of Chapter 2E of the Corporations Act.

Ms Chen is a Director and therefore is a related party of the Company for the purposes of section 208 of the Corporations Act.

The Board has resolved that the giving of financial benefit to Mr Chen falls within one of the exceptions, being benefits that are reasonable remuneration. Therefore, the Company is not required to obtain Shareholder approval for the purposes of Chapter 2E of the Corporations Act.

11.3 Listing Rule 10.11

Refer to Section 9.3 for a summary of Listing Rule 10.11.

The issue of Director Shares to Ms Chen (and/or her nominee(s)) falls within Listing Rule 10.11.1 as Ms Chen is a related party of the Company, and does not fall within any of the exceptions in Listing Rule 10.12. Therefore, the issue of the Director Shares requires Shareholder approval under Listing Rule 10.11.

If Shareholder approval is obtained under Listing Rule 10.11, Shareholder approval is not required under Listing Rule 7.1. Pursuant to Listing Rule 7.2, exception 14, the effect of passing Resolution 12 will be to allow the Company to issue Director Shares to Ms Chen (and/or her nominee(s)) without using the Company's 15% Placement Capacity under Listing Rule 7.1.

If Resolution 12 is not passed, the Company will not issue the Director Shares to Ms Chen (and/or her nominee(s)) in lieu of her Director Fees. The Company will be required to settle the Director Fees owed to Ms Chen in cash.

11.4 Specific information required by Listing Rule 10.13

The following information in relation to Resolution 12 is provided to Shareholders for the purposes of Listing Rule 10.13:

(a) The Director Shares will be issued to Ms Chen (and/or her nominee(s)) pursuant to Resolution 12.

(b) Ms Chen falls within Listing Rule 10.11.1 as she is a Director and therefore is a related party of the Company.

(c) The maximum number of Shares to be issued to Ms Chen (and/or her nominee(s)) will be calculated based on formula:

$$Director\ Shares = \frac{Amount}{Conversion\ Price}$$

For the purposes of the formula:

Amount	Up to $73,197.50
Issue Price	The 30-day VWAP of Shares for the period commencing 28 October 2025 to 27 November 2025

(d) The Director Shares are fully paid ordinary Shares and rank equally in all respects with the existing Shares.

(e) The Director Shares will be issued to Ms Chen (and/or her nominee(s)) no later than one month after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the Listing Rules).

(f) The issue price of the Director Shares will be calculated using the formula in Section 11.4(c)

(g) No funds will be raised from the issue of Director Shares as they will be issued for nil cash consideration. The Director Shares are being issued to Ms Chen (and/or her nominee(s)) in lieu of cash payments of her Director Fees.

(h) The current remuneration package of Ms Chen is as follows:

Director[1]	Cash salary and fees ($)	Cash bonus ($)	Non-monetary ($)	Superannuation ($)	Share based payments[3] ($)	Total ($)
Ms Sophie Chen[2]	-	-	-	5,405	45,045	**50,450**

Notes:

1. Remuneration for the financial year ended 30 June 2025.
2. Ms Sophie Chen was appointed as a non-executive Director on 31 October 2024. Ms Chen's remuneration package is for the period 31 October 2024 to 30 June 2025.
3. The issue of Shares was approved by Shareholders at the Company's general meeting on 15 September 2025.

(i) Ms Chen has an interest in Resolution 12 and therefore believes it inappropriate to make a recommendation.

(j) The Director Shares will be issued under Ms Chen's non-executive Director agreement. Under the non-executive Director agreement, Ms Chen agreed to receive a gross annual remuneration from the Company of $73,197.50 (exclusive of statutory superannuation contributions), to be settled via the issue of fully paid ordinary Shares, issued at the 30-day VWAP of Shares for the period commencing 28 October 2025 to 27 November 2025, subject to Shareholder approval. The non-executive Director agreement contains customary terms for the appointment of a non-executive Director.

(k) A voting exclusion statement is included in the Notice for Resolution 12.

(l) Other than the information above and otherwise detailed in the Notice, the Company believes there is no other information that would be reasonably required by Shareholders to pass Resolution 12.

11.5 Potential Dilution

The exact number of Director Shares to be issued to Ms Chen (and/or her nominees) under Resolution 12 will be depend on the 30-day VWAP of Shares for the period commencing 28 October 2025 to 27 November 2025

The number of Director Shares to be issued cannot be ascertained as at the date of the Notice. Below are worked examples of the number of Director Shares that may be issued under Resolution 12 based on a range of the issue price of Shares.

Share Price	Maximum No. of Director Shares	Shares Currently on Issue	Dilution Effect
$0.03	2,439,915	151,072,424	1.59%
$0.06	1,219,958	151,072,424	0.80%
$0.09	813,306	151,072,424	0.54%

Note: The above table is for illustrative purposes only.

11.6 Board recommendation

The Board (excluding Ms Sophie Chen, due to her person interest in Resolution 12) recommends that Shareholders vote in favour of Resolution 12.

12 Resolution 13 – Section 195 Approval

12.1 General

In accordance with section 195 of the Corporations Act, a director of a public company may not vote or be present during meetings of directors when matters in which that director holds a 'material personal interest' are being considered.

Mr Hornby, Ms Chen and Mr O'Brien have a material personal interest in the outcome of Resolutions 6 to 11 (inclusive).

In the absence of this Resolution 13, the Directors may not be able to form a quorum at directors meetings necessary to carry out the terms of Resolutions 6 to 11 (inclusive).

The Directors accordingly exercise their right under section 195(4) of the Corporations Act to put the issue to Shareholders to resolve.

Resolution 13 is an ordinary resolution.

12.2 Director Recommendation

The Directors consider that, given the subject matter of Resolution 13, it would be inappropriate for the Directors to make a recommendation to Shareholders on Resolution 13.

Schedule 1

Definitions

In the Notice and this Explanatory Memorandum, words importing the singular include the plural and vice versa.

$ means Australian Dollars.

15% Placement Capacity has the meaning given in Section 6.1.

10% Placement Facility has the meaning given in Section 6.1.

10% Placement Period has the meaning given in Section 6.2(f).

Annual Report means the Directors' Report, the Financial Report and the Auditor's Report in respect to the financial year ended 30 June 2025.

ASX means ASX Limited (ACN 008 624 691) and, where the context permits, the Australian Securities Exchange operated by ASX Limited.

AWST means Australian Western Standard Time, being the time in Perth, Western Australia.

Auditor's Report means the auditor's report on the Financial Report.

Board means the board of Directors.

Chair means the chair of the Company.

Chairperson means the person appointed to chair the Meeting, or any part of the Meeting, convened by the Notice.

Closely Related Party has the meaning given in section 9 of the Corporations Act.

Company means Hiremii Limited (ACN 642 994 214).

Company Secretary means the company secretary of the Company.

Constitution means the constitution of the Company as at the commencement of the Meeting.

Corporations Act means the *Corporations Act 2001* (Cth).

Director means a director of the Company.

Director Fees has the meaning given in Section 11.1

Directors' Report means the annual directors' report prepared under Chapter 2M of the Corporations Act for the Company and its controlled entities.

Director Shares has the meaning given in Section 11.1

Eligible Entity has the same meaning as in the Listing Rules.

Equity Security has the same meaning as in the Listing Rules.

Explanatory Memorandum means this explanatory memorandum which forms part of the Notice.

Financial Report means the annual financial report prepared under Chapter 2M of the Corporations Act of the Company and its controlled entities.

Joint Lead Managers means Bay Financial and Sequoia Corporate Finance.

Key Management Personnel has the same meaning as in the accounting standards issued by the Australian Accounting Standards Board and means those persons having authority and responsibility for planning, directing and controlling the activities of the Company, or if the Company is part of a consolidated entity, of the consolidated entity, directly or indirectly, including any director (whether executive or otherwise) of the Company, or if the Company is part of a consolidated entity, of an entity within the consolidated group.

Listing Rules means the listing rules of ASX.

Managing Director means the managing Director of the Company.

Meeting has the meaning in the introductory paragraph of the Notice.

Notice means the notice of meeting which comprises of the notice, agenda, Explanatory Memorandum and Proxy Form.

Option means an option which entitles the holder to subscribe for a Share.

Performance Right means a right to be issued a Share on the satisfaction of a specified vesting condition.

Placement has the meaning given in Section 7.1.

Placement Option has the meaning given in Section 7.1.

Proxy Form means the proxy form attached to the Notice.

Remuneration Report means the remuneration report of the Company contained in the Directors' Report.

Resolution means a resolution contained in the Notice.

Section means a section of this Explanatory Memorandum.

Share means a fully paid ordinary share in the capital of the Company.

Shareholder means a registered holder of a Share.

Strike has the meaning given in Section 4.

Tranche 1 Placement has the meaning given in Section 7.1.

Tranche 2 Placement has the meaning given in Section 7.1.

Tranche 1 Placement Options has the meaning given in Section 7.1.

Tranche 2 Placement Options has the meaning given in Section 7.1.

Tranche 1 Placement Shares has the meaning given in Section 7.1.

Tranche 2 Placement Shares has the meaning given in Section 7.1.

VWAP means volume weighted average price.

Schedule 2

Terms and Conditions of Placement Options

1 Entitlement

Each Option entitles the holder (**Holder**) to subscribe for one Share upon exercise.

2 Exercise Price and Expiry Date

The exercise price of each Option is $0.05 (**Exercise Price**).

Each Option will expiry two (2) years from the date of issue (**Expiry Date**).

3 Exercise Period

Each Option may be exercised at any time prior to the Expiry Date (**Exercise Period**). Any Option unexercised within the Exercise Period will automatically lapse.

4 Notice of Exercise

The Options may be exercised by notice in writing to the Company (**Notice of Exercise**) and payment of the applicable Exercise Price for each Option being exercised.

5 Shares issued on Exercise

Shares issued on exercise of the Options rank equally with the Shares on issue and will be free of all encumbrances, liens and third party interests.

6 Minimum Exercise Price

The Options must be exercised in multiples of one thousand (1,000) unless fewer than one thousand (1,000) Options are held by a Holder.

7 **Quotation of Shares**

If admitted to the official list of ASX at the time, the Company will apply to ASX for quotation of the Shares issued upon the exercise of the Options.

8 Timing of issue of Shares and quotation of Shares on exercise

Within five (5) Business Days after the later of the following:

(a) receipt of a Notice of Exercise and payment of the applicable Exercise Price for each Option being exercised in accordance with clause 4; and

(b) when excluded information in respect to the Company (as defined in section 708A(7) of the Corporations Act) (if any) ceases to be excluded information. If there is no such information the relevant date will be the date of receipt of a Notice of Exercise as detailed in clause 4 above),

the Company will:

(c) allot and issue the number of Shares required under these terms and conditions in respect of the number of Options specified in the Notice of Exercise and for which cleared funds have been received by the Company;

(d) as soon as reasonably practicable and if required, give ASX a notice that complies with section 708A(5)(e) of the Corporations Act, or, if the Company is unable to issue such a notice, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors; and

(e) if admitted to the official list of ASX at the time, apply for official quotation on ASX of Shares issued pursuant to the exercise of the Options.

If, for any reason, a Notice of Exercise delivered under clause 4 is not effective and to ensure that an offer for sale of the Shares does not require disclosure to investors, the Company must, no later than 20 business days after becoming aware of such notice being ineffective, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors.

9 Participation in new issues

A Holder who holds Options is not entitled to:

(a) notice of, or to vote or attend at, a meeting of Shareholders;

(b) receive any dividends declared by the Company; and

(c) participate in any new issues of securities offered to Shareholders during the term of the Options,

unless and until the Options are exercised and the Holder holds Shares.

10 Adjustment for bonus issues of Shares

If the Company makes a bonus issue of Shares or securities to eligible Shareholders (other than an issue in lieu of, or in satisfaction of, dividends or by way of dividend reinvestment):

(a) the number of Shares which must be issued on exercise of an Option will be increased by the number of Shares which the Holder would have received if the Holder had exercised the Option before the record date for the bonus issue; and

(b) no change will be made to the Exercise Price.

11 Adjustment for reorganisation

If there is any reconstruction of the issued share capital of the Company, the rights of the Holder may be varied to comply with the Listing Rules that apply to the reconstruction at the time of the reconstruction.

12 Adjustment for rights issue

If the Company makes an issue of Shares pro rata to existing Shareholders (other than an issue in lieu of in satisfaction of dividends or by way of dividend reinvestment) the Exercise Price of an Option will be reduced according to the following formula:

$$\boldsymbol{O' = O - \frac{E[P - (S + D)]}{N + 1}}$$

where:

O' = the new Exercise Price of the Option.

O = the old Exercise Price of the Option.

E = the number of underlying Shares into which one Option is exercisable.

P = average market price per Share weighted by reference to volume of the underlying Shares during the 5 trading days ending on the day before the ex rights date or ex entitlements date.

S = the subscription price of a Share under the pro rata issue.

D = the dividend due but not yet paid on the existing underlying Shares (except those to be issued under the pro rata issue).

N = the number of Shares with rights or entitlements that must be held to receive a right to one new share.

13 Quotation of Options

The Company will not seek official quotation of any Options.

14 Transferability

The Options are not transferable.

Hiremii Limited
ABN 48 642 994 214

Need assistance?

Phone:
1300 850 505 (within Australia)
+61 3 9415 4000 (outside Australia)

Online:
www.investorcentre.com/contact

YOUR VOTE IS IMPORTANT

For your proxy appointment to be effective it must be received by **12:00pm (AWST) on Tuesday, 25 November 2025.**

Proxy Form

How to Vote on Items of Business

All your securities will be voted in accordance with your directions.

APPOINTMENT OF PROXY

Voting 100% of your holding: Direct your proxy how to vote by marking one of the boxes opposite each item of business. If you do not mark a box your proxy may vote or abstain as they choose (to the extent permitted by law). If you mark more than one box on an item your vote will be invalid on that item.

Voting a portion of your holding: Indicate a portion of your voting rights by inserting the percentage or number of securities you wish to vote in the For, Against or Abstain box or boxes. The sum of the votes cast must not exceed your voting entitlement or 100%.

Appointing a second proxy: You are entitled to appoint up to two proxies to attend the meeting and vote on a poll. If you appoint two proxies you must specify the percentage of votes or number of securities for each proxy, otherwise each proxy may exercise half of the votes. When appointing a second proxy write both names and the percentage of votes or number of securities for each in Step 1 overleaf.

A proxy need not be a securityholder of the Company.

SIGNING INSTRUCTIONS FOR POSTAL FORMS

Individual: Where the holding is in one name, the securityholder must sign.

Joint Holding: Where the holding is in more than one name, all of the securityholders should sign.

Power of Attorney: If you have not already lodged the Power of Attorney with the registry, please attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: Where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the Corporations Act 2001) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please sign in the appropriate place to indicate the office held. Delete titles as applicable.

PARTICIPATING IN THE MEETING

Corporate Representative
If a representative of a corporate securityholder or proxy is to participate in the meeting you will need to provide the appropriate “Appointment of Corporate Representative”. A form may be obtained from Computershare or online at www.investorcentre.com/au and select "Printable Forms".

Lodge your Proxy Form:

Online:

Lodge your vote online at www.investorvote.com.au using your secure access information or use your mobile device to scan the personalised QR code.

Your secure access information is

Control Number: 188407

SRN/HIN:

For Intermediary Online subscribers (custodians) go to www.intermediaryonline.com

By Mail:

Computershare Investor Services Pty Limited
GPO Box 242
Melbourne VIC 3001
Australia

By Fax:

1800 783 447 within Australia or
+61 3 9473 2555 outside Australia

PLEASE NOTE: For security reasons it is important that you keep your SRN/HIN confidential.

You may elect to receive meeting-related documents, or request a particular one, in electronic or physical form and may elect not to receive annual reports. To do so, contact Computershare.

Change of address. If incorrect, mark this box and make the correction in the space to the left. Securityholders sponsored by a broker (reference number commences with '**X**') should advise your broker of any changes.

Proxy Form

Please mark X to indicate your directions

Step 1 Appoint a Proxy to Vote on Your Behalf

I/We being a member/s of Hiremii Limited hereby appoint

the Chairperson of the Meeting **OR**

PLEASE NOTE: Leave this box blank if you have selected the Chairperson of the Meeting. Do not insert your own name(s).

or failing the individual or body corporate named, or if no individual or body corporate is named, the Chairperson of the Meeting, as my/our proxy to act generally at the meeting on my/our behalf and to vote in accordance with the following directions (or if no directions have been given, and to the extent permitted by law, as the proxy sees fit) at the Annual General Meeting of Hiremii Limited to be held at the offices of RSM, Level 32, 2 The Esplanade, Perth, Western Australia on Thursday, 27 November 2025 at 12:00pm (AWST) and at any adjournment or postponement of that meeting.

Chairperson authorised to exercise undirected proxies on remuneration related resolutions: Where I/we have appointed the Chairperson of the Meeting as my/our proxy (or the Chairperson becomes my/our proxy by default), I/we expressly authorise the Chairperson to exercise my/our proxy on Resolutions 1 and 12 (except where I/we have indicated a different voting intention in step 2) even though Resolutions 1 and 12 are connected directly or indirectly with the remuneration of a member of key management personnel, which includes the Chairperson.

Important Note: If the Chairperson of the Meeting is (or becomes) your proxy you can direct the Chairperson to vote for or against or abstain from voting on Resolutions 1 and 12 by marking the appropriate box in step 2.

Step 2 Items of Business

PLEASE NOTE: If you mark the **Abstain** box for an item, you are directing your proxy not to vote on your behalf on a show of hands or a poll and your votes will not be counted in computing the required majority.

		For	Against	Abstain
1	Remuneration Report			
2	Re-election of Mr David Buckingham as Director			
3	Approval of 10% Placement Facility			
4	Ratification of T1 Placement Shares issued under Listing Rule 7.1A			
5	Ratification of T1 Placement Options issued under Listing Rule 7.1			
6	Issue of Tranche 2 Placement Shares to Mr Andrew Hornby			
7	Issue of Tranche 2 Placement Options to Mr Andrew Hornby			
8	Issue of Tranche 2 Placement Shares to Ms Sophie Chen			
9	Issue of Tranche 2 Placement Options to Ms Sophie Chen			
10	Issue of Tranche 2 Placement Shares to Mr Conor O'Brien			
11	Issue of Tranche 2 Placement Options to Mr Conor O'Brien			
12	Issue of Director Shares to Ms Sophie Chen in lieu of Director Fees			
13	Section 195 Approval			

The Chairperson of the Meeting intends to vote undirected proxies in favour of each item of business. In exceptional circumstances, the Chairperson of the Meeting may change his/her voting intention on any resolution, in which case an ASX announcement will be made.

Step 3 Signature of Securityholder(s)

This section must be completed.

Individual or Securityholder 1	Securityholder 2	Securityholder 3	
			/ /
Sole Director & Sole Company Secretary	Director	Director/Company Secretary	Date

Update your communication details *(Optional)*

By providing your email address, you consent to receive future Notice of Meeting & Proxy communications electronically

Mobile Number

Email Address